Tel Aviv, Israel

Anahit Karapetian


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anahit Karapetian: Pioneering Early Cancer Diagnosis

Introduction

Anahit Karapetian, an innovative inventor based in Tel Aviv, Israel, has made significant strides in the field of medical diagnostics. With her groundbreaking patent, she is paving the way for early cancer detection, which is crucial for enhancing treatment success rates.

Latest Patents

Anahit holds a single, notable patent titled "Method for the early diagnosis of cancer." This invention introduces a unique methodology focused on determining the relative fraction of microorganisms derived from a fecal sample. By comparing this fraction to the total count of microorganisms, her approach provides a new avenue for diagnosing cancer in subjects. The process involves isolating specific microorganisms from fecal samples and assessing their cancerolytic activity in relation to cancer cells. The cancerolytic activity is then quantified using a tumor cell necrosis index (TCNI), facilitating the identification of cancer presence or absence through non-invasive means.

Career Highlights

Throughout her career, Anahit has demonstrated a commitment to advancing medical science. Her role at Era-Massis, Inc. places her at the forefront of research and innovation in diagnostics. With her academic background and practical experience, she has developed methods that hold the potential to revolutionize cancer diagnosis.

Collaborations

Anahit collaborates with esteemed colleagues such as Gil Tenne and Mark L. Levitt. Their joint efforts emphasize the importance of teamwork in scientific research, combining their expertise to enhance the effectiveness and reach of their innovations.

Conclusion

Anahit Karapetian stands as a beacon of innovation in the medical field, particularly in cancer diagnosis. Her pioneering method not only aids in the timely detection of cancer but also exemplifies the potential of interdisciplinary collaborations in research and development. As she continues her work with Era-Massis, Inc., the impact of her innovations may very well lead to significant advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…